Treatment response to olanzapine and haloperidol and its association with dopamine D2 receptor occupancy in first-episode psychosis

Canadian Journal of Psychiatry

Volumn 50, Issue 8, 2005, Pages 462-469

  Zipursky, Robert B ^a,b   Christensen, Bruce K ^a,b   Daskalakis, Zafiris ^a,b   Epstein, Irvin ^a,b   Roy, Paul ^c,d   Furimsky, Ivana ^b   Sanger, Todd ^e   Kapur, Shitij ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Dopamine; First episode; Haloperidol; Olanzapine; PET; Positron emission tomography; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; HALOPERIDOL; OLANZAPINE; PROLACTIN; RACLOPRIDE C 11; BENZODIAZEPINE DERIVATIVE; DIAGNOSTIC AGENT; NEUROLEPTIC AGENT; RACLOPRIDE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; ACUTE DISEASE; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; SCHIZOPHRENIA; SCINTISCANNING;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 25444493183     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674370505000806     Document Type: Article

References (27)

1. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-83.
2. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-9.
3. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, and others. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-8.
4. Nordstrom A-L, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, and others. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effect: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
5. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514 -20.
6. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286 -93.
7. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-44.
8. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2-dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57:103-8.
9. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, and others. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-8.
10. Kapur S, Zipursky RB, Remington G. Clinical and therapeutic implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-93.
11. Pilowsky L, Busatto G, Taylor M, Costa D, Sharma T, Sigmundsson T, and others. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine-a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996;124:148-53.
12. Pilowsky L, Mulligan R, Acton P, Ell P, Costa D, Kerwin R. Limbic selectivity of clozapine. Lancet 1997;350:490-1.
13. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, and others. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996;153:948-50.
14. Kapur S, Zipursky RB, Roy P, Jones C, Remington G, Reed K, and others. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl) 1997;131:148-52.
15. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997;17:308-13.
16. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley Jr C, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156:79-87.
17. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull 1999;25:721-9.
18. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, and others. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-404.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association; 1994.
20. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/ PSY SCREEN) New York: Biometrics Research, New York State Psychiatric Institute; 2002.
21. Kay SR, Opler LA, Lindenmayer J-P. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatr Res 1987;23:99-110.
22. Guy W. ECDEU assessment manual for psychopharmacology. Revised ed. Rockville (MD): US Dept of Health, Education and Welfare, National Institute of Mental Health; 1976. Publication (ADM) 76-338.
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-9.
24. Barnes T. A rating scale for drug induced akathisia. Br J Psychiatry 1989;154:672-6.
25. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003;160:303-9.
26. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, and others. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
27. Beasley Jr CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, and others. Olanzapine versus placebo and haloperidol:acute phase results of the North American Double-Blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.